Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Akero Therapeutics Inc (AKRO)

Akero Therapeutics Inc (AKRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,499,006
  • Shares Outstanding, K 82,324
  • Annual Sales, $ 0 K
  • Annual Income, $ -252,060 K
  • EBIT $ -330 M
  • EBITDA $ -343 M
  • 60-Month Beta -0.40
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.56
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.94
  • Most Recent Earnings $-0.99 on 11/07/25
  • Next Earnings Date 02/27/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.00
  • Number of Estimates 5
  • High Estimate -0.93
  • Low Estimate -1.11
  • Prior Year -0.99
  • Growth Rate Est. (year over year) -1.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
54.02 +1.17%
on 11/10/25
54.83 -0.32%
on 12/08/25
+0.61 (+1.13%)
since 11/07/25
3-Month
41.77 +30.84%
on 09/15/25
54.83 -0.32%
on 12/08/25
+10.08 (+22.62%)
since 09/08/25
52-Week
21.34 +156.09%
on 01/14/25
58.40 -6.42%
on 01/27/25
+23.54 (+75.67%)
since 12/06/24

Most Recent Stories

More News
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Akero Therapeutics...

AKRO : 54.65 (+0.18%)
Halper Sadeh LLC Encourages WOW, AKRO, HFWA, BRY Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

BRY : 3.26 (+2.19%)
AKRO : 54.65 (+0.18%)
HFWA : 24.53 (-0.20%)
WOW : 5.21 (+0.19%)
Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

AKRO : 54.65 (+0.18%)
NIC : 124.56 (-0.14%)
BRNS : 0.7015 (-1.07%)
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)

PHILADELPHIA , Nov. 12, 2025 /PRNewswire/ --  Berger Montague PC  advises shareholders of  Akero Therapeutics, Inc. ("Akero" or the "Company") about an investigation into the Company...

AKRO : 54.65 (+0.18%)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF, AKRO, NIC, and BRNS

NEW YORK , Nov. 10, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

NIC : 124.56 (-0.14%)
AKRO : 54.65 (+0.18%)
BRNS : 0.7015 (-1.07%)
CRTAF : 13.0000 (+3.59%)
Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025

Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY trial and indicate potential to reduce risk of disease progression in compensated...

AKRO : 54.65 (+0.18%)
Halper Sadeh LLC Encourages AKRO, CADE, FSUN Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

CADE : 43.86 (+0.44%)
FSUN : 38.54 (+0.21%)
AKRO : 54.65 (+0.18%)
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)

PHILADELPHIA , Nov. 4, 2025 /PRNewswire/ --  Berger Montague PC  advises shareholders of  Akero Therapeutics, Inc. ("Akero" or the "Company") about an investigation into the Company...

AKRO : 54.65 (+0.18%)
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)

PHILADELPHIA , Oct. 29, 2025 /PRNewswire/ --  Berger Montague PC advises shareholders of  Akero Therapeutics, Inc. ("Akero" or the "Company") about an investigation into the Company...

AKRO : 54.65 (+0.18%)
Halper Sadeh LLC Encourages FFWM, AKRO, CCRD Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

FFWM : 6.16 (-0.16%)
AKRO : 54.65 (+0.18%)
CCRD : 23.60 (-2.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Akero Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing transformational treatments for non-alcoholic steatohepatitis and other serious metabolic disorders. The company's product pipeline consists of AKR-001, for the treatment of non-alcoholic steatohepatitis, which...

See More

Key Turning Points

3rd Resistance Point 55.32
2nd Resistance Point 55.07
1st Resistance Point 54.86
Last Price 54.65
1st Support Level 54.40
2nd Support Level 54.16
3rd Support Level 53.95

See More

52-Week High 58.40
Last Price 54.65
Fibonacci 61.8% 44.24
Fibonacci 50% 39.87
Fibonacci 38.2% 35.50
52-Week Low 21.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar